VWF and Genetic thrombotic microangiopathy: These observations, coupled with laboratory findings of low ADAMTS13 activity (i.e., a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13, a circulating enzyme which cleaves von Willebrand factor (VWF) multimers reducing their activity) to von VWF antigen (VWF:Ag) ratio [5], elevated lactate dehydrogenase (LDH) [6] and interleukin-6 (IL-6), thrombocytopenia [7, 8], and anemia [9], suggest that COVID-19 may be associated with a thrombotic microangiopathy– (TMA–) like condition.